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Abstract
To celebrate the first 10 years of Nature Reviews Genetics, we asked eight leading researchers for
their views on the key developments in genetics and genomics in the past decade and the prospects
for the future. Their responses highlight the incredible changes that the field has seen, from the
explosion of genomic data and the many possibilities it has opened up to the ability to
reprogramme adult cells to pluripotency. The way ahead looks similarly exciting as we address
questions such as how cells function as systems and how complex interactions among genetics,
epigenetics and the environment combine to shape phenotypes.
What advances in the past decade have particularly excited and surprised
you?
Edith Heard
It is amazing to see how epigenetics has been propelled into the headlines over the past
decade. On the one hand, it has been hailed as an explanation for inter- and intra-individual
diversity, and on the other, as a purveyor of hidden information — beyond genes — that can
be influenced by intrinsic and extrinsic fluctuations. The ‘hype’ surrounding epigenetics
may partly be due to the fact that, since the human genome was sequenced 10 years ago, we
have been confronted with the reality, and perhaps inevitability, of our genetic constitution.
Epigenetics may provide hope that we are more than just the sequence of our genes — and
that our destiny and that of our children can be shaped, to some extent, by our lifestyle and
environment. The recent groundbreaking discoveries on induced pluripotency have also
brought the reversible nature of epigenetic states to the forefront. Such reversibility brings
much hope for treating diseases such as cancer, which have not just a genetic but also an
epigenetic basis, for which ‘epidrugs’ can be used to reverse aberrant epigenetic changes
(epimutations).
What has caused this excitement? Major advances in our understanding of epigenetic
mechanisms have been made in the past decade. Our grasp of the molecular basis of
epigenetics has expanded well beyond DNA methylation, which was previously the best
known epigenetic mark. It now includes other chromatin components, such as histone
variants and histone modifications, as well as associated protein complexes.
The nature and mechanism of action of complexes such as Polycomb and Trithorax —
which can modify histones, alter chromatin structure and shape the epigenome, as well as
ensuring heritability of gene expression states — are starting to be unravelled1. One
surprising advance has been the finding that chromatin states can be incredibly labile. For
example, histone methylation was initially believed to be a very stable modification, but the
past decade has seen the discovery not only of many of the enzymes that lay down such
histone modifications1,2 but also of those that remove them3. Even DNA methylation, long
thought to be stable and reversible only through passive loss during DNA replication, may
be subject to active removal under some circumstances4.
Advances over the past decade have also highlighted the fact that epigenetic memory may
consist of more than one modification and has to be considered in the context of time — cell
cycle, developmental and generational. Different molecular marks may act in a cascade of
events to ensure heritability of a particular state. An elegant illustration of this has come
from the exciting findings in Schizosaccharomyces pombe, which reveal that transcription
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and RNAi work together with histone modifying and binding complexes to ensure the
accurate propagation of inactivity during the cell cycle5. In a more developmental context,
recent work on X-chromosome inactivation illustrates how a cascade of epigenetic changes
can ensure reversible silencing of a chromosome during early mouse embryogenesis6.
Developmental plasticity of epigenetic marks is a recurring theme.
These studies have started to provide answers to some fundamental questions in epigenetics:
how is the memory of a particular state ensured through cell division or even across
generations? And how is this memory forgotten or erased under particular circumstances
(for example, in the germ line) or by accident (for example, in cancer)?
Sarah Tishkoff
One of the most exciting advances has been the development of low-cost, high-throughput
methodologies for studying human genome-scale variation. These technologies have
provided unprecedented knowledge about the structure of the human genome and human
origins. They have also led to the identification of genetic variants with roles in human
phenotypic variation, both in relation to disease susceptibility and evolutionary adaptation.
Advances in genome-wide association (GWA) studies — which have used microarray
technology for SNP genotyping and have included meta-analyses of tens of thousands of
individuals — have identified loci associated with common variable traits including skin,
hair and eye colour and height (for example, REFS 7,8), which has shed light on human
adaptation and evolution. Several approaches have also been developed for scanning the
genome for targets of natural selection and have identified regions that have important roles
in adaptation to diverse environments during human evolution. These include loci that have
a role in lactose tolerance9,10, skin pigmentation11, adaptation to high-altitude12 and
malaria resistance13,14. Some variants that are targets of natural selection also have a role in
susceptibility to common disease; for example, apolipoprotein l, 1 (APOL1) variants
associated with resistance to sleeping sickness are also associated with risk for kidney
disease in individuals of African ancestry15.
The development of statistical approaches for analysing genome-scale variation has also
been crucially important. For example, methods based on principal components analysis
(PcA)16 and STRUCTURE17 analysis have facilitated studies of fine-scale population
structure and individual ancestry. The results have demonstrated a remarkable correlation
between genetic variation and the geographical origin of individuals18, even at the regional
level in Europe19.
Sequencing technologies have also made a strong contribution to understanding human
genetic variation. The first two draft human genome sequences were completed in 2001
(REFS 20,21), and the first human genome was resequenced using next-generation
sequencing (NGS) technology, at a fraction of the cost, in 2008 (REF. 22). As of 2010 more
than 15 complete human genomes — originating from Europe, Asia and Africa — have
been resequenced, and that number is likely to rise exponentially in the next several years as
costs fall. These studies have identified millions of SNPs and indicate that individual
genomes may differ by megabases of sequence because of structural variation, including
insertions, deletions and inversions.
Furthermore, low-coverage sequencing of the Neanderthal genome23 has demonstrated that
it has remarkable similarity to the modern human genome, and that the two species diverged
less than 500,000 years ago. Those genomic regions that differ between the two appear to be
involved in skin physiology and, possibly, social behaviour23. These studies have also raised
the intriguing possibility that there may have been low levels of gene flow between
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Neanderthals and modern humans in Eurasia, suggesting that our genomes may contain
mosaic sequences.
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*Listed in alphabetical order.
John A. Todd
It has been a decade of relief and enlightenment for the study of the genetics of common,
multifactorial diseases. It was a long wait. We realized in the early 1990s that linkage
studies, which work well in highly penetrant, rare, Mendelian diseases, weren’t going to be
very helpful. What large linkage studies did tell us about these diseases was that there are
no, or extremely few, causal loci that have large individual effects on phenotype. This is true
no matter what the sequence complexity of the causal loci, from genes with multiple causal
Heard et al. Page 5













alleles24 to structural variants, such as highly repetitive DNA sequences25, that may be
inaccessible to the current high-throughput genotyping platforms.
Even in the run-up to affordable GWA studies in sufficiently large numbers of samples,
there were (mainly futile) debates on genetic models: were common variants responsible for
the strong familial clustering of many common diseases? Or were low-frequency to rare
variants involved? However, it was obvious that wide spectrums of allele effect sizes and
frequencies would underlie the inheritance of common disease. It was also obvious that,
when sequencing technology at last broke free from the small-scale capillary format,
variants of increasingly low frequencies would be discovered that contribute to disease
risk24. GWA studies confirmed (and extended) Fisher’s conclusion of 1918 that many
common diseases and other human characteristics are determined by inheriting a sufficient
dose of susceptibility alleles from a large number of loci across the genome in a disease-
permissive environment26. For example, the familial clustering of type 1 diabetes27,
schizophrenia28 and height8 can be explained almost completely by common variation.
Nevertheless, largely specious debates rage on about ‘missing heritability’. unfortunately,
many authors are actually referring to familial clustering (based on similarity or co-
occurrence of traits among first-degree family members), which is caused by intrafamilial
sharing of numerous alleles and environmental factors. Familial clustering could be
overestimated27, and in the future, with larger sample sizes and better genetic coverage, we
will begin to define how much of it is due to environmental exposures. One intriguing
possibility is that a small portion of familial clustering is due to transgenerational effects —
gene–environmental interaction events in parents, grandparents or beyond that alter the
phenotypes and behaviours of the current generation29.
Regardless of genetic models or statistical methods, the most important outcome of
reproducible GWA study results is what they have told us about biology and mechanisms of
disease. GWA studies have been, as expected, particularly revealing in two main aspects.
First, common alterations to gene expression and function do not map to obviously
functional DNA changes, illustrating how little we know about genome function. Second,
from the genes and pathways revealed by GWA studies, major mechanistic insights have
been gained. To take a recent example, a GWA study of lung cancer shows that this disease
involves genetic susceptibility to behaviour with regard to smoking, such as its initiation,
dependency on smoking and even the ability to stop the habit30.
For me, the surprise of the decade has been the discovery of an entire parallel universe of
small (and large) non-protein-coding RNAs and their regulation of protein-coding gene
expression31. A recent, beautiful example32 is the alteration of the critical tumour
suppressor gene phosphatase and tensin homolog (PTEN) through competition for the
regulatory microRNA (miRNA) between the classic PTEN gene and the mRNA of its
pseudogene (yes, I said pseudogene), PTENP1. Now, proteins are being discovered — such
as ROQUIN (also known as Rc3H1)33 and dead end homologue 1 (DND1)29 — that bind
RNA and modulate miRNA function. What I find particularly fascinating about these two
proteins is their potential effects on gene–environment interactions. They are both localized
in stress granules, which are cytoplasmic sites involved in mRNA metabolism that are
formed in response to stress, including in germ cells (oocytes and sperm). The functions of
the non-coding RNAs, mRNAs and RNA-binding proteins in these granules could underlie
transgenerational effects transmitted by germ cells29. Transgenerational phenotypes are now
being documented convincingly in mouse models, including the DND1 gene itself29.
Transgenerational effects, including epigenetic variability34, could help to explain the rapid
increases in certain common diseases in countries with modern health care and lifestyles,
including interactions between many environmental factors, not least common viral
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infections that remain largely uncontrolled, our gut microbiomes and our highly
polymorphic genomes26.
Marc Vidal
At the end of a decade of unprecedented productivity in biological data accumulation, the
excitement generated is somewhat tempered by a surprising level of confusion.
The most compelling and surprising excitement has emerged from the incredible amount of
empirical information that has been gathered on genomes, transcriptomes, proteomes and
interactomes. A recurrent theme emerging from such systematic, unbiased, high-throughput
analyses is how much more complicated the molecular organization of the cell appears to be
relative to what was originally revealed using focused, hypothesis-driven, reductionist
molecular biology approaches. Transcriptomes, both protein-coding and non-coding, are
more complex than initially thought, by at least an order of magnitude, with more than 80%
of the genome seemingly transcribed in humans. The proteome is also more difficult to
grasp than originally anticipated, considering the potential amount of alternative splicing,
posttranslational modifications, protease-induced cleavages, disordered domains and
allosteric changes that have been found to take place. And last, the landscape of
macromolecular interactions is richer than imagined. For example, estimates of the numbers
of protein–protein and DNA–protein interactions that can happen in a single cell are in the
range of 105 to 106. Interactome maps, together with genome-wide gene knockout and
knockdown analyses that are coupled to transcriptomic measurements, have revealed that
molecular pathways, rather than being linear, independent from or parallel to each other, are
instead incredibly intertwined and form very complex biological networks.
In an odd twist of events, these substantial advances, which were originally aimed at
‘finding and understanding all genes’, are somewhat undermining the concept of the term
‘gene’ itself. I find this of crucial importance, because the gene is often considered the
fundamental unit of biology. The ‘gene number paradox’, according to which organisms of
different complexity have similar numbers of protein-coding genes (for example, humans21
and worms35 both have approximately 20,000 genes), illustrates how a certain perception of
biology revolves around the notion that to understand an organism, we need only ‘to
understand all its genes’. consider the ambitious, exciting project framed in January 2000
and funded by the US National Science Foundation “… to understand a function for all
genes of Arabidopsis by 2010.”36 Ten years on, things appear more complicated.
Part of the confusion goes back to how we interchangeably use the concept of the gene as
both a molecular encoding unit and a unit of heredity37. but this classical problem has been
enormously amplified in the past decade. At the molecular level, it is increasingly harder to
define the exact boundaries of both protein- and non-coding genes. At the level of heredity,
GWA studies now identify genes whose relative contribution to a particular phenotype of
interest can be no more than a few per cent.
The word ‘gene’ was coined 101 years ago by Wilhelm Johannsen38. This centennial
anniversary was largely ignored last year compared to the publicity surrounding the 150th
anniversary of Darwin’s On the Origin of Species or the 100th anniversary of Einstein’s
paper on the theory of relativity. could powerful far-reaching notions that emerged at the
dawn of molecular biology — such as beadle and Tatum’s ‘one gene, one enzyme, one
function’ hypothesis39 or crick’s ‘DNA makes RNA makes protein’ central dogma40 — be
running out of steam? What could replace, or at least complement, such powerful notions to
improve our understanding of biology in the next decade and beyond?
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Genomics, though a thoroughly descriptive discipline, is revolutionizing our understanding
of the nature of evolutionary change in a way that was unexpected to me. Most amazing to
me is the emerging role of transposable elements in evolutionary change. This became
apparent through the comparative sequencing of many related genomes, both revealing the
dynamical nature of genomes as well as the parts transposable elements play in that process.
Certainly, the idea that transposable elements may have an important role in the evolution of
gene regulatory networks is not new, but it is fair to say that this idea had only a limited
influence on mainstream evolutionary genetics for most of its existence.
What is different now is that we can see exactly what transposable elements are contributing
to evolutionary change. They are not just another source of random perturbation of the
genetic material, they also have a constructive role, one that single-nucleotide substitutions
do not have. The evidence is now pouring in, and it is greatly acknowledged in the field of
genomics, but the message has not yet reached evolutionary genetics, not to speak of other
areas of biology.
There is a long list of novel genetic elements that transposable elements can create41. To me,
the most surprising is their role in the creation of novel transcription factor proteins. The
poster child of a key regulatory gene is paired box gene 6 (PAX6), and it has been found to
be derived from a transposase41! But the major constructive role of transposable elements
probably is their ability to create new cis-regulatory elements. The reason is that
transposable elements come prefabricated with a large number of transcription factor
binding sites in their sequence, which predisposes them to become cis-regulatory elements.
This opens the door to major and fast rewiring of gene regulatory networks, and
transposable elements are thus important agents in the origin of major innovations42.
Why are these findings leading to a revolution in evolutionary biology? One of the basic
ideas at the root of the Darwinian theory of evolution is the idea of uniformitarianism. It
says that past change is due to exactly the same kinds of processes that we can observe
today. This makes a lot of sense and allows a mechanistic understanding of past events. But
what the new research about transposable elements tells us is that this principle is true only
to a certain degree. It turns out that the kinds of genetic changes possible at any particular
time in history and in each lineage depend on what kinds of transposable elements are
present and active43. Because of the biased nature of the changes transposable elements
cause, certain changes are more likely at certain times in history, and in certain lineages,
than at other times or in other lineages. That means that the potential for evolutionary
innovations is heterogeneous in time, among lineages and among tissue types. Transposable
elements are active in a lineage for only a limited amount of time, and evolutionary
innovation seems to be particularly intense during these periods in history. Since each
lineage has its own transposable elements, it is also clear that the likelihood of genetic
innovations differs simply because one lineage has a certain kind of transposable element
and others do not. But all this flies into the face of uniformitarianism and thus forces us to
rethink how genetic change is happening in evolution.
Jun Wang
Within the 10 years following the announcement of the landmark completion of the Human
Genome Project21 there have been an amazing number of revolutionary innovations in the
field of genomics that have aimed at answering the question, ‘is deciphering the genome
useful?’ That is, will genomics help to improve our health and our everyday life? Although
there is still no consensus, scientists have completed numerous milestone projects that
indicate the answer is probably a qualified yes.
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The first set of goals was aimed at ‘defining genomes’ — establishing data to serve as a new
and fundamental resource for genetics. Scientists have sequenced an impressive list of
genomes, including those of humans20,44, standard model animals (for example, mice45)
and plants (for example, Arabidopsis thaliana46), economical animals (for example, the
bovine genome47) and crop plants (for example, rice48) and many others. Large-scale
efforts aiming to generate reference data sets, such as the HapMap project49, are also a part
of this — that is, defining the genomes of multiple individuals.
The process of defining genomes has been accompanied by other crucial advances: the
development, organization and management of consortia to carry out these large-scale
scientific projects; the establishment of data access conventions; and the development of
many novel approaches and tools for data analysis. These factors have jointly established a
maturing model for defining genomes and for making that information broadly available.
They have also had a surprising and profound impact on the entire biological community by
promoting collaboration and establishing goals for quantifying, standardizing and sharing all
types of biological and medical data50.
The second set of goals has been in ‘understanding genomes’ — making sense of each
nucleotide of these sequences. This has primarily involved large-scale projects doing
association studies51 and quantitative trait loci mapping52 or direct functional experiments
on specific genes and genetic variations53. The findings have demonstrated possibilities for
linking the genetic code to a phenotype (but not vice versa). Another focus has been
investigating the relationship between genotypes and gene expression54 and between
epigenetics and expression55 to understand the intermediate levels of the organization of life
that lie between genome and phenotype. Altogether, this work has begun to characterize the
digital information underlying the mechanisms of life, which sheds light on how to go
forward after the era of defining genomes.
Still, after a decade of criticism, controversy and success, the interpretation of genomes (as
expected) lags far behind the progress in genome sequencing and, with a few exceptions,
surprisingly little has been done to develop applications using genomes. That the genome is
useful has been a basic, but uncertain, tenet over the past 10 years. While it is now one that
seems far clearer, it is time for the genome to fulfil its promise.
Detlef Weigel
Foremost is the phenomenal increase in DNA sequencing capacity, which very few, if any,
of us anticipated 10 years ago, but I would like to emphasize a few areas in which plant
biology has been in the vanguard of genetics or has made unique contributions.
An excellent example is the realization that small RNAs are ubiquitous, that they come in
many different flavours, that they affect an enormously broad range of biological processes,
that they do so through many different mechanisms and that they themselves are subject to
multiple modes of regulation. As in animals, plant miRNAs can control target genes by
preventing translation of their mRNAs. In addition, they often guide mRNA cleavage, either
directly or indirectly through secondary small RNAs56. Furthermore, miRNAs themselves
are not only regulated transcriptionally but also through decoys called target mimics — a
mechanism discovered in plants57.
The first whole-genome maps of small RNAs were produced in plants58; most recently, this
has led to the remarkable finding that plants ‘allow’ transposons to become active in
vegetative tissue so that they can make use of the resulting small RNAs in order to silence
these harmful elements in generative cells59. Plant genomics has also led the way in linking
small interfering RNAs and DNA methylation on a whole-genome scale. Ironically, the
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breakthrough advances in producing whole-genome DNA methylation maps were widely
noticed only once the methods developed for plants were applied to human cells60. In the
general area of gene silencing, the flowering regulator FLC has provided a powerful
platform for discovering several principles of chromatin modification, including ones
involving non-coding RNAs, that also apply to animals61.
There are several other areas in which plant geneticists have made dramatic progress during
the past decade, not least in identifying the receptors for all of the major plant hormones,
most of which operate through mechanisms that are rather different from those employed in
animal signal transduction62. And in those cases in which similar types of molecules are
recognized, as with steroids63, plants have found unique solutions to the problem of relaying
information between cells and organs.
Richard Young
The most exciting advances have been in the area of cellular reprogramming with defined
transcription factors. In 2006 Yamanaka and colleagues showed that transient expression of
four transcription factors could reprogramme somatic cells to a pluripotent embryonic stem
(ES) cell-like state64. Before this discovery, it was evident that the nuclei of differentiated
cells could be reprogrammed when transferred into an oocyte, but the nature of the
reprogramming factors was a mystery. The discovery that a few key transcription factors are
sufficient to reprogramme the vertebrate genome has profoundly affected many fields of
biomedical research and the quest for regenerative medicine.
The ability to generate induced pluripotent stem (iPS) cells has allowed investigators to
create disease- and patient-specific embryonic stem cells65. Disease-specific iPS cells have
already been generated from patients with various genetic disorders, allowing researchers to
study the effects of specific mutations on cellular function and providing cellular reagents
for drug screening. Patient-specific iPS cells may provide the raw material for tissue-
replacement therapies that should circumvent immune rejection. The promise of
regenerative medicine seems more tangible with iPS cells, prompting discussion of the
challenges that must be addressed before therapies based on these or other stem cells are
used in the clinic65–68.
Recent studies have shown that some differentiated cell types can be directly reprogrammed
into other differentiated cell types. For example, forced expression of three transcription
factors induces the direct conversion of pancreatic exocrine cells into insulin-producing
endocrine cells69. Similarly, transient expression of three transcription factors is sufficient to
reprogramme fibroblasts into neurons70.
The ability to reprogramme cells has also improved our understanding of how cell state and
differentiation are controlled. The reprogramming experience suggests that both embryonic
and differentiated cells rely on a small collection of key transcription factors to establish and
maintain cell state71. In the best-studied cases, the exogenous reprogramming transcription
factors jump-start their endogenous counterparts, which form a positive feedback loop that
maintains the cellular control circuitry after the exogenous factors are silenced or
removed72. It is conceivable that many cell types rely on a small set of these ‘master’
transcription factors to maintain a stable and specific cell state, and that reprogramming into
a broad spectrum of clinically useful cell types simply awaits the identification of these
factors.
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What are the key prospects and challenges in the next few years?
E.H.
One major challenge that cuts across many fields will be to integrate the massive data sets
that are being generated by NGS technology. We now have access to epigenomes,
transcriptomes, small RNA and replication timing profiles. We also know a lot more about
nuclear organization and chromosome structure thanks to chromosome conformation capture
technologies. Furthermore, such data sets can be analysed in the context of allelic
differences, providing important insights into regulatory variation. These studies represent a
gold mine of information and have already provided a glimpse of the sophistication with
which the genome is organized and interpreted. For example, we can at last define the
molecular signatures associated with different expression states and thus understand the
nature of euchromatin and heterochromatin. Based on studies in lower eukaryotes,
integrating these huge data sets, modelling the results and obtaining testable predictions
should be achievable aims for systems biologists. The question now is, how easy will this be
in higher eukaryotes? For example, repetitive sequences — long considered as junk DNA
but now recognized as key structural and functional components of the genome — are an
important feature of higher eukaryotes but represent a major bioinformatics challenge.
Another challenge is to go beyond the static view that NGS data provide, as well as the
heterogeneity that they can hide (in populations of cells). NGS-based approaches are starting
to be applied to specific developmental stages, or to cells obtained by sorting, grown under
different conditions or taken from mutant backgrounds. Single-cell approaches are also
coming of age for transcriptome analyses103, and high-resolution microscopy and live cell-
imaging techniques are providing unprecedented views of nuclear dynamics and gene
regulation73. Obtaining an integrated four-dimensional view of nuclear structure and
function should at last be possible.
In the field of epigenetics, many challenges remain. One issue concerns the extent to which
gene epigenetics relies on negative and positive feedback loops. We also have yet to
understand the detailed molecular mechanisms by which an expressed or silent state can be
transmitted through cell division. How exactly are chromatin states replicated74? To what
extent are histones themselves the carriers of epigenetic information? What is the exact role
of Polycomb or Trithorax complexes in propagating epigenetic states? Is RNA involved and,
if so, how? Is transcription itself an epigenetic propagator? How does nuclear organization
influence chromatin heritability1,74?
Perhaps one of the most important and exciting challenges over the next few years will be to
determine the extent to which epigenetic modifications can be transgenerational and the
impact that such heritable epimutations or epivariants might have on quantitative traits, or
on disease predisposition75. The potential implications of this ‘hidden’ heritability are
enormous. understanding the molecular mechanisms by which transgenerational heritability
of chromatin states occurs is clearly a tenable prospect in the next few years for plants76, but
is likely to be more of a challenge in mammals, in which germline erasure predominates and
functional studies are more laborious77.
S.T.
Despite the advances in genomics technologies and genome-wide scans of selection and
disease association over the past decade, there have been few success stories identifying
functional genetic variants that have a role in complex traits such as height, diabetes,
cardiovascular disease or autism. Many of the loci identified by GWA studies account for
just a fraction of the phenotypic variation and disease risk and, in the majority of cases,
biologically functional variants have not yet been identified. Thus, a key challenge in the
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future will be to detect the ‘missing heritability’ in GWA studies. Strategies for tackling this
issue will include the determination of gene–environment and gene–gene interactions,
exploration of how rare variants contribute to phenotypic variability, and determining the
extent of structural variation in ethnically diverse populations and its role in producing
phenotypic diversity.
Importantly, although many of the alleles underlying complex trait variation are likely to
influence gene expression, the identification of regulatory variants is particularly
challenging. This is partly because we are just beginning to understand the important effects
of small RNAs and epigenetic factors on gene regulation. However, recent advances in the
development of high-throughput genomics technologies now facilitate approaches that
integrate genomics (for example, DNA sequencing and chromatin immunoprecipitation
followed by sequencing (chIP–seq)), transcriptomics (for example, RNA sequencing),
proteomics and epigenomic data from assorted tissues to identify both coding and non-
coding variants that impact variable traits. A systems biology approach that explores how
naturally occurring genetic variants perturb genetic and transcriptional networks may be
particularly successful for dissecting the genetic architecture of complex variable traits.
Equally important will be an understanding of how these networks are influenced by
environmental factors, including diet, lifestyle and disease status.
As the cost of resequencing decreases, the sequencing of exomes, and eventually whole
genomes, at the population level is becoming feasible. The 1000 Genomes Project has
already initiated population-level analyses of whole-genome variation. In the future, it will
be crucial to include ethnically diverse populations, which may have population-specific
variants owing to their demographic history or to local adaptation. Africa, in particular, has
been underrepresented in genomics and GWA studies. It will be important to tackle this
imbalance, given that African populations contain the greatest levels of human genetic
variation and high levels of genetic substructure, and because this region is the source of the
world-wide range expansion of all modern humans over the past 100,000 years. Africa also
has high levels of both communicable and non-communicable disease. In order to facilitate
GWA studies in Africans, SNP arrays will need to be developed based on SNPs identified
through resequencing studies in Africans. In general, population-level resequencing studies
will require the development of computational methods for storing and analysing large
amounts of data and for determining which of the millions of SNPs likely to be identified
are functionally relevant.
Novel approaches will also need to be developed to identify genetic variants that are targets
of natural selection and have a role in adaptation. Current approaches are most effective for
identifying recent strong selection of novel adaptive variation. One of the greatest challenges
in the future will be to identify more complex signatures of natural selection, as would be
expected for genetic variants that have a role in complex adaptive traits that are influenced
by multiple loci and the environment, by selection acting on standing variation and by
fluctuating selection that changes with the environment. Additionally, methods are needed
for detecting natural selection acting on pathways rather than single loci. Thus, the
integration of systems biology approaches and studies of natural selection may be
particularly informative. Finally, but crucially, the identification of causal variants will
require in vitro and in vivo functional assays in order to elucidate the biological roles of
adaptive variants.
J.A.T.
A major task will be to correlate gene expression and function with genome variation. Small
differences in the expression and function of certain genes can result in specific cell
phenotypes that can have highly significant, pleiotropic effects on development as well as on
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susceptibility and resistance to disease32,78. Fortunately, we are not without tools to explore
these links, many of them recently developed or enhanced significantly by NGS78. For
example, we can survey, on a genome-wide basis, which sequences bind which transcription
factors (chIP–seq); which sequences are conserved or not between species; which enhancer
sequences loop round to contact promoter sequences (chromosome conformational capture);
which regions are differentially methylated; and which genome variants correlate with gene
splicing, transcription and translation, and with susceptibility to disease.
We need to further improve these methods by making them as quantitative as possible. We
also need to invent and improve similarly enabling tools for protein and cell analyses in
order to correlate the presence of certain alleles with protein and cellular phenotypes. High-
affinity monoclonal antibodies for each gene product and their splice isoforms would be
incredibly helpful. We need to apply these methods to cell populations derived from healthy
individuals and those with disease79 or disease risk factors. A particular focus should be on
patients undergoing treatment, and on the evaluation of new therapies and risk-lowering
prevention strategies. Once we have identified the inherited phenotypes that precede disease
diagnosis, we can begin to unravel disease mechanisms that could be targeted specifically by
future therapeutics.
In general, however, we cannot expect health benefits from genetic- and genomics-derived
knowledge of mechanisms of disease to happen any faster than the 20 years it can take from
molecule to approved drug in the traditional pharmaceutical pipeline. For example, 15 years
since they were first developed, microarrays for gene expression analysis are only just
yielding their first clinical applications in cancer and in heart transplant rejection80.
Modification of environmental factors and behaviour may provide substantial health benefits
in the future, with GWA study results providing key guidelines about which ones to
modify24,26,30.
M.V.
The complexity of transcriptomes, proteomes and interactomes revealed in the past decade
relates back to classical problems. In addition to coining the word ‘gene’, Johannsen defined
the words ‘genotype’ and ‘phenotype’38 from his observation that self-fertilized inbred ‘pure
lines’ of bean plants (read ‘isogenic’) followed a normal distribution of pod sizes. The
underappreciated take-home message was that identical genotypes do not always give rise to
identical phenotypes.
Of course, the environment comes to mind as a mediator between genotype and phenotype,
but there is clearly more to it. A century after Johannsen, genotype–phenotype relationships
are far from being fully understood. Identical twins have different fingerprints. Incomplete
pene-trance and variable expressivity are observed more often than not, even in genetic
experiments that analyse the effects of mutations under well-controlled conditions. Only
relatively small proportions of genes appear to be essential, at least in simple unicellular
organisms such as yeast81,82. On the other hand, powerful GWA studies aimed at
understanding complex traits in humans are revealing more contributing loci than were
originally anticipated83.
The next decade will bring new inroads to the challenge of relating genotype to phenotype.
Paradoxically, from an arguably confusing situation concerning what genes ‘are’ and ‘do’ (if
they do anything) at the end of the last decade, the 2010s are poised to deliver fundamentally
new ways of comprehending biological problems, further clarifying the understanding of
genetics, and perhaps treating and curing disease.
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Significant answers will probably come from the increasingly clear perception that virtually
no gene product functions in isolation. Proteins, miRNAs, regulatory DNA sites — that is,
all macromolecular entities — need to physically, biochemically or functionally interact
with others to perform their cellular functions. Intimately connected biological components
form complex, dynamic and logical networks or systems, which exhibit emergent and non-
intuitive properties84. A systems approach to biological questions is likely to illuminate
genotype– phenotype relationships. Observable phenotypes should be considered as the
manifestation of precisely those systems properties, rather than simply the result of genomic
variations. Phenotypes are probably more directly related to systems properties than they are
to DNA and ‘genes’. Mutations affect encoded macromolecular components of the cell,
which in turn affect the properties of systems.
The idea that multi-scale, complex systems formed by interacting macromolecules and
metabolites, cells, organs and organisms underlie life is not new. Visionaries such as
Delbrück85, Waddington86, Monod and Jacob87, among others, proposed such thinking in
the mid-twentieth century. There was a powerful resurgence of these concepts over the past
decade, together with the development of sophisticated informatic and imaging tools,
combined with the engineering and physics concepts of control and graph theory. The
resulting systems-level understanding of what life is may materialize as one of the major
ideas of biology88.
Provided that enough funding can be dedicated to mapping, modelling, perturbing and
synthetically reconstituting biological networks and systems, the next decade should give
fresh insights into the fundamental question of genotype–phenotype relationships.
Perturbations of systems properties will probably be found to underlie many complex traits.
G.P.W.
One important outstanding issue to understand is the origin of the networks that determine
cell type identity. In part due to the efforts in stem cell research, we now have a fairly good
understanding of the mechanistic basis of cell type identity71. It turns out that a cell’s
identity is mediated by a core gene regulatory network that cooperatively regulates target
genes that, in turn, cause the cell-type-specific phenotype. This means that the hierarchy is
very shallow, with one level comprising the core network and a second level made up of the
target genes. There is preliminary evidence that this organization might also be applicable to
the identity of multicellular characters89. Hence, character identity, and thus homology —
one of the most difficult concepts in evolutionary biology — might be understandable at the
molecular level. Now the challenge is to understand the genetic events that lead to the origin
of novel cell type identity networks90. This is a largely untouched area of research.
In my laboratory we think that the origin of these networks involves molecular mechanisms
that are different from nucleotide substitutions in existing cis-regulatory elements42. Among
the molecular changes that are likely to be involved in the evolution of novel gene
regulatory networks are new cis-regulatory elements derived from transposable elements, as
discussed above, and the evolution of novel transcription factor complexes91. The latter
seems to be important since cell-type-specific gene regulation, at least in vertebrates, seems
to depend on the formation of transcription factor complexes that mediate the cooperative
action of the participating transcription factors71. How the origin of novel cis-regulatory
elements derived from transposable elements and the evolution of novel transcription factor
complexes ultimately lead to innovations, such as novel cell types, is currently unclear.
The challenge is to find examples in which the biological significance of the genetic changes
is certain; that is, what was the ancestral situation, what is the function of the derived cell
type and when did it happen in evolution? It is hard to make sense of the vast amount of
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differences one can identify by comparing the genomes and transcriptomes of two or three
randomly chosen organisms, such as humans, mice and zebrafish. Research has to focus on
specific evolutionary events in which novel characters, such as novel cell types, hair or
pregnancy, evolved. The experimental work has to focus on organisms that are informative
about these transitions; that is, they need to be well placed on the phylogeny to reveal the
relevant changes. The threshold of doing that, that is, experiments with minimal reliance on
traditional model organisms, is becoming lower with new technology. Now one needs only a
genome sequence to do transcriptomics (instead of investing in a microarray), and methods
for manipulating gene expression, such as RNAi, are more and more universal. For this
research, what an appropriate model organism is has to be redefined in terms of how
informative a species is in a phylogenetic context.
J.W.
The past decade has witnessed the impact of genomes on scientific research. We also have
more confidence than we had 10 years ago in the premise that genomes will bring new
applications and be useful to the general public. Only a few applications are currently being
developed by virtue of genomics, but I feel we are now entering the stage at which scientists
will be asking, ‘How can we use the genome?’ In the coming 2–3 years, I believe genomics
work will still primarily concentrate on deciphering and understanding, but using genomes
in a broader context than basic research will become especially important. To be able to do
this, it is essential that work focuses on innovation in experimental technologies and
computational methodologies.
Collecting biological information (deciphering) using high-throughput, precise profiling of
data on multiple biological levels will be crucial. Although second-generation technology
has solved many throughput issues for nucleotide sequencing, several problems remain. The
refinement of computational algorithms for nucleotide sequencing and profiling is required
to ease downstream analyses. Issues related to wet-lab protocols, such as obtaining adequate
starting material and the presence of experimental bias, still create serious limitations.
Additionally, the throughput levels and bioinformatics tools for non-nucleotide biological
information — such as proteins, metabolites, phenotypes and even environmental factors —
are currently no match for those for nucleotide sequencing. It is exciting to note that efforts
to address this issue have already begun (for example, studies relating to the impact of
environment on complex disease92), but more needs to be done to tackle this challenge.
Interpreting these disparate types of biological information (‘understanding’), given the
complexity of biological interactions, will require truly integrative analyses from a more
mature form of systems biology that deals with combinations of genomic, epigenetic,
expression, metabolism and phenotypic data. Reaching this goal will take far more than 2–3
years; thus, the challenge over these coming years will be to develop proper algorithms and
analytical tools to handle such unprecedented large-scale multidimensional networked data.
This is a highly achievable goal.
In the field of medicine, with the technology we have today we should be able to decipher
nearly all confirmed monogenic disorders and, with a focus on developing better integrative
analyses and tools, we will begin to gain a more complete understanding of complex
disorders, including cancer. New and improved medications will come from the
identification of a wide range of novel druggable targets. Of greatest interest will be
progress in medical genomics and personal genomics, which may shift some of our focus
from drug development to a less expensive and more productive predictive and preventive
health care system. In agriculture and ecology, we will see the identification and analysis of
key genes and their activities in animals, plants and microbes that contribute to important
economical and ecological phenotypes. We will then be able to establish methods for
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applying this information to guide the breeding and cultivation of new varieties or strains in
an environmentally safe way.
As I see it, the coming 2–3 years will be the incubation period for large-scale applied
genomics and bio-industry. It will certainly be a historical time point when scientists and the
public alike are convinced that, after years of effort, genomics is useful.
D.W.
By studying genetic variation, we can begin to interpret the results from mechanistic
approaches in an evolutionary and ecological context. In humans, the excitement about the
use of GWA studies for the discovery of alleles that affect disease susceptibility or other
important traits has recently become a bit muted because the effect sizes and the fraction of
explained variation tend to be rather small.
By contrast, proof-of-principle studies in plants have already shown that GWA studies, even
with relatively small sample sizes, can pick up loci that account for a large fraction of
phenotypic variation, and these approaches are further enhanced by combining them with
association analyses in populations derived from crosses93. Moreover, the inbred nature of
many species, particularly of crops, greatly facilitates the comprehensive discovery of
sequence variants and thus should speed up the identification of polymorphisms that are
causal for phenotypic differences.
Perhaps the most promising short-term prospect is in exploiting new sequencing
technologies for high-precision linkage mapping in experimental populations that segregate
for a trait of interest. In model organisms, one can use pools of mutant individuals to both
map and identify in a single sequencing reaction sequence polymorphisms that are causal for
mutant phenotypes94. This approach can be readily extended to polygenic traits, which
typically underlie phenotypic differences between wild strains95. In principle, this makes
any sexually reproducing organism amenable to genetic analysis. We will see a new era in
which the proverbial ‘awesome power of genetics’ is brought to bear on any species that has
at least one special trait of interest, such as production of a valuable chemical or resistance
to a dangerous crop pathogen. All that one needs is individuals that differ in this trait,
crosses between these individuals and, ideally, the ability to phenotype large segregating
populations with thousands of individuals, so that high-resolution mapping of recombinants
allows very accurate triangulation of the causal gene (or genes). Performing genetic studies
in much broader groups of species will allow us to harness the evolutionary and ecological
history embedded in the genomes of all sorts of organisms that survive under an incredibly
broad range of environmental conditions.
Sequencing will also play an important part in understanding the extended phenotype,
through the analysis of microbial communities. Most of us have suffered from the
consequences of having the wrong type of bacteria thrive in our intestines, which
dramatically underscores how important microbes are for our wellbeing. Indeed, we have
already learned how diverse the bacteria are that live in the human gut96. Similarly, there are
many reasons to believe that bacteria, fungi, oomycetes and other microbes play an
essential, yet poorly understood, part in helping plants to extract resources from their
environment. Moreover, as with animals, most microbes do not cause disease on most plants
because they express conserved pathogen-associated molecular patterns (PAMPs). To
overcome PAMP-triggered basal defences that limit microbial growth, successful pathogens
need to deploy virulence proteins97. Yet, despite PAMP recognition, huge numbers of
microbes live relatively peacefully on and in multicellular organisms. I am certain that we
will soon find out how the host distinguishes beneficial or innocuous microbes from harmful
ones. An exciting opportunity is offered by the prospect of exploiting this knowledge to
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engineer new, advantageous plant–microbe associations to enhance the performance of
crops and trees.
Finally, there are two related areas in which I believe plants will lead the way. One is in
revealing cell-type-specific gene expression patterns98, a key step for deciphering the
transcriptional code embedded in cis-regulatory elements. (I admit to having believed 10
years ago that we would have mastered this challenge by now.) In addition, physical models
of growing plant organs have recently become impressively sophisticated99, and integrating
them with cell-type-specific models of gene regulatory networks holds exceptional promise
for being able to predict the development of an entire organism. Combining these, in turn,
with knowledge of genetic variation will usher in a new era of true systems biology.
R.Y.
I believe we will see some very exciting and important advances in our understanding of
development and disease that will challenge us in new ways.
I anticipate substantial advances in developmental biology, in which studies of the
regulatory mechanisms that control cell state will continue to produce new and surprising
insights. For example, recent insights into gene silencing, which is crucial for establishing
and maintaining cell states, suggest that non-coding RNA (ncRNA) molecules are frequently
involved100. Much remains to be learned about ncRNA genes in humans and the functions
of various classes of ncRNAs in different cell types. Because some regulatory ncRNAs are
short-lived, it will be a challenge to identify all of these and ascertain their functions.
The study of disease-specific iPS cells will lead to new insights into disease mechanisms,
and these should ultimately facilitate the development of novel therapeutic interventions.
Novel therapies generally take at least a decade to develop, so it will continue to be a major
challenge to accelerate delivery of useful therapies to the clinic. After extensive preclinical
tests, a substantial fraction of drugs fail to show efficacy in the clinic. Clinical trial design is
now beginning to take advantage of the genetics of individuals, which may increase the
success rate of novel therapeutics.
The cost of genome sequencing will become so low in the next 2–3 years that thousands of
individuals will be sequenced. Consequently, we will begin to reclassify disease based on
genome sequence. The combination of information from genome sequencing and iPS cell
studies will significantly accelerate our understanding of disease mechanisms. Screening of
chemical compound libraries for molecules that affect iPS cell phenotypes will become
common, providing hits that may accelerate the development of lead compounds for new
therapeutics. Collaborations between biologists, chemists, computer scientists and clinicians
will become ever more valuable and essential.
The concept that transcription factors control gene expression programmes was established
half a century ago101, at the same time that Gurdon showed by nuclear transfer that
differentiated intestinal cells in amphibians retain all of the genetic information needed to
produce an entire frog102. Transcription factors recognize specific DNA sequences and
instruct the transcription apparatus to produce RNA, thus controlling gene expression
programmes, development and cell states. The ability of specific transcription factors to
reprogramme cell states is the ultimate demonstration of these concepts. In this important
area, at least two major challenges face the biomedical community. The first is to begin the
process of discovering how the ~1,500 human transcription factors control the hundreds of
cell states that exist in humans. The second is to learn how to modify the activities of
transcription factors directly using small-molecule chemistry. We will begin to address these
challenges in the next 2 years.
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